Login / Signup

Safety of systemic treatments for Behçet's syndrome.

Giuseppe LopalcoDonato RiganteGiuseppe LopalcoGiacomo EmmiVincenzo VeneritoAntonio VitaleGiovanna CapozioNunzio DenoraClaudia FabianiFlorenzo Iannone
Published in: Expert opinion on drug safety (2020)
The greatest experience in the management of BS has been achieved with the employment of monoclonal anti-tumor necrosis factor antibodies which have been advocated for BS refractory manifestations. Moreover, interleukin-1 inhibitors have proven to be effective as well as safe, despite escalation of their dosage, especially to manage the most severe and difficult-to-treat ocular manifestations. However, general treatment of BS patients remains awkward as protean clinical features may respond differently to the same treatment or even worsen. Therefore, patients' safety for therapies used in BS promotes the implementation of precision medicine, which could help targeting accurately the pathogenetic mechanisms concealed behind specific clinical phenotypes.
Keyphrases